Hennion & Walsh Asset Management Inc. Lowers Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Hennion & Walsh Asset Management Inc. lowered its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 1.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 13,678 shares of the company’s stock after selling 232 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Krystal Biotech were worth $2,143,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Summit Trail Advisors LLC acquired a new stake in Krystal Biotech in the third quarter valued at about $1,893,000. Swiss National Bank lifted its position in shares of Krystal Biotech by 8.0% during the 3rd quarter. Swiss National Bank now owns 39,100 shares of the company’s stock valued at $7,117,000 after acquiring an additional 2,900 shares during the period. Sei Investments Co. lifted its position in shares of Krystal Biotech by 18.9% during the 2nd quarter. Sei Investments Co. now owns 40,115 shares of the company’s stock valued at $7,367,000 after acquiring an additional 6,363 shares during the period. Shaker Investments LLC OH acquired a new stake in shares of Krystal Biotech during the 3rd quarter valued at approximately $532,000. Finally, Citigroup Inc. lifted its position in shares of Krystal Biotech by 65.4% during the 3rd quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock valued at $6,386,000 after acquiring an additional 13,874 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Chardan Capital reiterated a “buy” rating and set a $212.00 price target on shares of Krystal Biotech in a research report on Wednesday, December 18th. Citigroup lifted their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Finally, HC Wainwright reiterated a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research report on Wednesday, December 18th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Krystal Biotech currently has an average rating of “Buy” and an average target price of $206.67.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock opened at $148.39 on Friday. Krystal Biotech, Inc. has a 1 year low of $107.50 and a 1 year high of $219.34. The company has a market capitalization of $4.27 billion, a P/E ratio of 83.84 and a beta of 0.85. The business has a 50 day moving average price of $170.98 and a 200 day moving average price of $182.12.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same period in the previous year, the firm posted ($0.67) EPS. The company’s quarterly revenue was up 879.9% compared to the same quarter last year. As a group, research analysts expect that Krystal Biotech, Inc. will post 3.03 EPS for the current fiscal year.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 14.10% of the stock is owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).